Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 18/20 | 0.67 |
| ▸ | DAGLB | Q8NCG7 | 4/20 | 0.62 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.60 |
| ▸ | ABHD6 | Q9BV23 | 10/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18936213 | 1.00 | DAGLA (0.67) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL18936215 | 1.00 | DAGLA (0.67) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL18935811 | 0.88 | DAGLA (0.63) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL20575954 | 0.86 | DAGLA (0.60) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL20575956 | 0.86 | DAGLA (0.60) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL18935652 | 0.86 | DAGLA (0.54) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL20576014 | 0.86 | DAGLA (0.60) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL13192448 | 0.85 | DAGLA (0.71) | DAGLADAGLBABHD6 | |
| SCHEMBL18935815 | 0.84 | DAGLA (0.61) | DAGLADAGLBDDHD2ABHD6 | |
| SCHEMBL18935818 | 0.84 | DAGLA (0.61) | DAGLADAGLBDDHD2ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583137-B2 | Triazole DAGLα inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-03-10 | — | — | US | disclosed |
| US-20180344729-A1 | TRIAZOLE DAGLAlpha INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2018-12-06 | — | — | US | disclosed |
| WO-2017096315-A1 | TRIAZOLE DAGL(α) INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10583137-B2 | Triazole DAGLα inhibitors | DAGLB, DAGLA, DGKB | DAGLA 2/4885DAGLB 1/4885DDHD2 2253/4885 |
| US-20180344729-A1 | TRIAZOLE DAGLAlpha INHIBITORS | DAGLB, DAGLA, DGKB | DAGLA 2/4885DAGLB 1/4885DDHD2 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.